Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial-Reference-Cited by-同舟云学术

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial

Published:2014-08-01 Issue:1 Volume:7 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Subbiah Vivek,Meric-Bernstam Funda,Mills Gordon B,Shaw Kenna R Mills,Bailey Ann Marie,Rao Priya,Ward John F,Pagliaro Lance C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-014-0052-x.pdf

Reference50 articles.

1. Kondagunta GV, Motzer RJ: Chemotherapy for advanced germ cell tumors. J Clin Oncol. 2006, 24 (35): 5493-5502.

2. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M:European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004, 15 (9): 1377-1399.

3. Sonpavde G, Hutson TE, Roth BJ: Management of recurrent testicular germ cell tumors. Oncologist. 2007, 12 (1): 51-61.

4. Kollmannsberger C, Nichols C, Bokemeyer C: Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer. 2006, 106 (6): 1217-1226.

5. Fukuda S, Shirahama T, Imazono Y, Tsushima T, Ohmori H, Kayajima T, Take S, Nishiyama K, Yonezawa S, Akiba S, Akiyama S, Ohi Y: Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer. 1999, 85 (6): 1323-1330.

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological and computational assessment of new synthesized nicotinamides as potential immunomodulatory VEGFR-2 inhibitors;Journal of Molecular Structure;2024-06

2. Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib;JCO Precision Oncology;2023-09

3. New fluorinated diarylureas linked to pyrrolo[2,3-d]pyrimidine scaffold as VEGFR-2 inhibitors: Molecular docking and biological evaluation;Bioorganic Chemistry;2022-10

4. Biomarkers in Urological Cancers;Biomarkers in Medicine;2022-08-30

5. Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation;Molecules;2022-08-08